Naproxen Heart Risk Isolated To One Clinical Study – Bayer/Roche
This article was originally published in The Tan Sheet
Executive Summary
The NIH-funded ADAPT trial was the only postmarketing study to show naproxen users experienced a heightened number of cardiovascular events, according to an analysis of several trials by Bayer and Roche